MEDBOX | Toolbox Biontech/Pfizer Comirnaty

TOOLBOX

Advanced search

Create your MEDBOX

TOOLBOX

Advanced search

Create your MEDBOX

LIST OPTIONS

FILTER BY LANGUAGE

FILTER BY COUNTRY

SORT BY

RESULTS/PAGE

LIST TYPE

23 records

	Good practice statement on the use of variant-containing COVID-19 vaccines World Health Organization WHO (2022) C_WHO View PDF(92) Download (32) Add to my MEDBOX Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.� Tags: vaccine, omicron, COVID-19, mRNA, variants, Source: https://apps.who.int/iris/rest/bitstream
	Manual del Vacunador Vacuna Comirnaty de Pfizer-BioNTech pediátrica de 5 a 11 años Campaña Nacional de Vacunación contra la COVID-19 Feraud, H. Ministerio de Salud Argentina (2022) C2 View PDF(50) Download (198) Add to my MEDBOX Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se había evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo Tags: SARS-CoV-2, corona virus, COVID-19, Vaccination, Argentina, Children, pédiatricos, niños, niña, Pfizer- BioNTech Comirnaty Vaccine, Source: https://bancos.salud.gob.ar/sites/defaul
	Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Vygen-Bonnet S, Koch J, Bogdan C, et al. (2022) C1 View PDF(150) Download (91) Add to my MEDBOX Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfempfehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, pediatrics, Children, Adolescents, booster, Source: https://www.rki.de/DE/Content/Infekt/Epi
	Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19 vaccine rollout, 1 February 2022 World Health Organization WHO (2022) C_WHO Open external link (259) Add to my MEDBOX Available in different languages Tags: cold chain, Vaccines, covid-19, Pfizer- BioNTech Comirnaty Vaccine, Source: https://apps.who.int/iris/handle/10665/3
	Recomendações provisórias para o uso da vacina Pfizer-BioNTech COVID-19, BNT162B2, na lista de uso de emergência. Orientação provisória 21 de janeiro de 2022 Organización Mundial de Saude and OPAS OPAS (2022) C_WHO View PDF(90) Download (41) Add to my MEDBOX Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo novamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas Tags: COVID-19, pfizer, Vaccination, Brazil, Source: https://iris.paho.org/bitstream/handle/1
	Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 Pfizer-BioNTech, BNT162b2, en vertu du protocole OMS d’autorisation d’utilisation d’urgence Organisation Mondiale de la Santé OMS (2022) C_WHO View PDF(65) Download (31) Add to my MEDBOX orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022 Tags: Vaccination, COVID-19, SARS-CoV-2, mRNA, strategy, recommendations, Source: https://apps.who.int/iris/bitstream/hand
	Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing World Health Organization WHO (2022) C_WHO View PDF(94) Download (49) Add to my MEDBOX These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. first issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/36172 Tags: Vaccination, COVID-19, SARS-CoV-2, mRNA, strategy, recommendations, biontech, pfizer, Comirnaty, Source: https://apps.who.int/iris/bitstream/hand
	ПАМЯТКА ПО ПРИМЕНЕНИЮ ВАКЦИНЫ ПРОТИВ COVID-19 Вакцина против COVID-19 компаний Pfizer–BioNTech, BNT162b2 World Health Organisation (WHO) (2021) C_WHO View PDF(59) Download (35) Add to my MEDBOX обновленная версия от 04/10/2021 Информация о введении вакцин Tags: COVID-19, vaccine, Storage, administration, pfizer, mRNA, vaccine candidates, Source: https://apps.who.int/iris/handle/10665/3
	Job aid for COVID-19 VACCINE administration - Pfizer–BioNTech COVID-19 vaccine, BNT162b2 World Health Organisation (WHO) (2021) C_WHO View PDF(54) Download (36) Add to my MEDBOX updated version: 04/10/2021 Information about vaccine administration Tags: COVID-19, vaccine, Storage, administration, pfizer, mRNA, vaccine candidates, Source: https://apps.who.int/iris/handle/10665/3
	Предварительные рекомендации по применению вакцины BNT162b2 Pfizer–BioNTech против COVID-19, включенной в список для использования в чрезвычайных ситуациях. World Health Organization WHO (2021) C_WHO View PDF(60) Download (27) Add to my MEDBOX Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г. Tags: Vaccination, COVID-19, SARS-CoV-2, mRNA, strategy, recommendations, biontech, pfizer, Comirnaty, Source: https://apps.who.int/iris/bitstream/hand

23 records

23 records